A Short Note On Hepatitis C And Its Effects

This research paper is going to review today’s silent killer, the Hepatitis C virus. This paper will talk about the description of the disease, the signs and symptoms, the etiology and risk factors, diagnostic studies, treatments and prognosis of this disease. I had lived with this disease for over ten years before diagnosed so it is important to understand the signs and symptoms so the disease can be identified and a treatment plan can be identified as the sooner it is treated the more likely it will eradicate the disease.

Although it is alarming about how expensive these drugs may cost, an inescapable idea that would have passed our brains several times already would be “Why should I care?” and that patients are only willing to pay this price because they need it because they are sick. Even if it may seem that we don’t empathize them, the overall perception is that since we don’t have hepatitis C, we would not have to worry about these price tags because we would never have to pay this fee. Because of this, although we may feel sympathy towards these patients, we are rarely able to perceive their problems at a personal level.

If Hepatitis C is caught in the early stages it is curable with medication. Watson points out that the medications that is used to treat Hepatitis C is very expensive and that people have a hard time paying for the cost. This results in people not getting the treatment due to the cost and this ultimately results in the person getting chronic Hepatitis C. Watson explains, “chronic Hepatitis C leads to cirrhosis of the liver, liver cancer or scarring of the liver” (personal communication, February 27, 2017). Watson states that within the past couple of years, drug companies have taken the cost of these medications into consideration and have set up payment plan options for people who suffer from Hepatitis C. Along with, some drug companies are now covering the entire cost of the medications depending on the person’s income level. Another development that has recently emerged is financial counselors. Watson explains that, “once a person tests positive for Hepatitis C they will be notified, control measures will be discussed and the nurse will refer them out to a financial counselor to figure out which route is best for them to get treatment” (personal communication, February 27, 2017). Surry County Health and Nutrition Center work closely with the financial counselors through Wake Forest Baptist Medical Center to get these

About 4.1 million people in Americans have the positive antibody to hepatitis C virus (HCV), and about 75 percent have permeant infection. Additionally, most of the infections happened 20 to 40 years ago, before the finding of HCV. Hepatitis C increased from 7,000 to 13,000 deaths in 2005. Furthermore, HCV develops slowly which increases the risk of severe complications in the infected people. Identification, death, and treatment are predicted to affect 35,000 by 2030. The Center for Disease Control (CDC) used antiviral therapy with PEGylated in clinical trials (Kalichman, Washington, Kegler, Grebler, Kalichman, Cherry, & Eaton, 2015). The CDC recommends a HCV one time test for people born between 1945 and 1965. The objective of this study was to thoroughly evaluate the amount of substance abusers infected with hepatitis C in the United States. Additionally, to observe the treatment of HCV. Currently Medicaid and Medicare repayment standards for sofosbuvir were calculated in all states, including the District of Columbia. Medicaid and Medicare covered the drug based on the following conditions; liver disease stage, HIV, and drug use. Approximately 42 states reimbursed the following criteria up to 74 percent for the drug sofobuvir. About two-thirds of the United States restricted the treatment centered on prescriber type. About 88 percent included drug abuse in their sofosbuvir admissibility measures. Finally, 50 percent required a date of abstinence and 64 percent required

As much as Medicaid being able to cover the costs of other expensive specialty drugs for other diseases such as HIV and cystic fibrosis but the case of Sovaldi is quite different given the fact that a large population suffers from the disease that it treats with the prevalence of hepatitis C among the Medicaid recipients being quite high. There have been several proposed federal solutions including; price controls, the creation of a supply chain where the federal government could buy quantities of the drug at a discount and also to sell the drug to the states at a low price. The issue has not yet been taken by the Congress with states still being given the

About 4.1 million people in Americans have the positive antibody for hepatitis C virus (HCV), and about 75% of them are persistently infected and most of the infections happened d 20 to 40 years ago, before the finding of HCV. Hepatitis C increased from 7,000 to 13,000 deaths in 2005. Furthermore, HCV develops slowly which increases the risk for severe complications in the infected people. Identification, death, and treatment is predicted to affect 35,000 by 2030. The Center for Disease Control (CDC) used antiviral therapy with PEGylated in clinical trials. The CDC recommends a HVC one time test for people born between 1945 and 1965.They observed testing by birth. The objective of this study was to thoroughly evaluate the amount of substance abuser infected with hepatitis C in the United States. Additional to observe the treatment of HVC. Currently Medicaid and Medicare repayment standards for sofosbuvir were calculated in all states including the District of Columbia. Medicaid and Medicare covered the drug based on the following classes liver disease stage, HIV, and drug use. Approximately 42 states reimbursed the following criteria up to 74% for the drug sofobuvir. About two thirds of the United States restricted the treatment centered on prescriber type. About 88% included drug abuse in their sofosbuvir admissibility measures. Finally 50% required a dated of abstinence and 64% required drug test. The latest drug to HVC is called Sovaldi and it costs $84,000 for the 12

Hepatitis C has been referred to as a "Silent Epidemic," since it usually progresses slowly over many years. Most people who are infected with hepatitis C are not aware of any noticeable symptoms for as long as one to two decades after they are infected. In fact, by the time symptoms appear, the virus has probably already begun to damage the liver. If the liver is injured and stops functioning, death will always be the outcome (Lieber). Liver failure from chronic hepatitis C is one of the most common causes of liver transplants in the United States.

The strain of genotypes is not differentiated by the severity of the disease. However, there will make a distinction in the regimen and the duration of the treatment (CDC, 2016). Treatment for chronic HCV is based on guidelines from the Infectious Diseases Society of America (IDSA) and the American Associations for the Study of Liver Diseases (AASLD). The criteria of who should receive the treatment include how much the virus in the body, the strain of hepatitis C, the degree of liver inflammation or damage, comorbidity, and response to previous treatment (Infectious Diseases Society of America [IDSA], 2016). The highest priority for treatment should give to a patient with advanced fibrosis and compensated cirrhosis (IDSA, 2016). Moreover, treatment priority should provide to the patient who has a high risk of transmitting the disease from and to others, such as individuals who are active injection drug users and hemodialysis patients (IDSA, 2016).

If someone is getting tested for Hepatitis C, they will first take an antibody test. This test will detect if antibodies are present in the blood, which will tell if the person has ever had Hepatitis C, not if they currently possess it (“Who Should”). If the antibody test comes back positive, a qualitative test will then be run. This test declares tells if someone is currently infected with Hepatitis C. A quantitative test can also be run, which shows the amount of Hepatitis C that is in the blood (“Who Should”). There are two main medications that are used to treat Hepatitis C. The first being Pegylated Interferon and another being Ribavirin. Both medications are used for the treatment of adult patients with chronic liver disease (FDA). These medications are used in place of the vaccine that has not been created for Hepatitis C. Therefore, Hepatitis C can be detected easily and is treatable.

There are a number of individuals who may be suffering from an illness and not even be aware they have an illness. One example of such illness is Hepatitis C (HCV). Hepatitis C is a severe disease of the liver. It is caused by the Hepatitis C virus (Centers for Disease Control and Prevention (CDC), 2015). As a result, Hepatitis C has been termed a silent epidemic (CDC, 2015). This is because a lot of individuals have Hepatitis C and don’t even realize they have the infection (CDC, 2015). As the infection begins to progress over time, it could cause acute issues to the liver (CDC, 2015). Those issues could be things like damage to the liver, the liver could fail to function, cirrhosis, or even cancer of the liver (CDC, 2015). However, screening for Hepatitis C will allow an individual to benefit from treatments that are available, hence eliminating the disease from the body and preventing the liver from undergoing any further damage (CDC, 2015).

Hepatitis C is a blood transmitted virus that has been know for substandard therapies/ drug treatments. When Mr. Parish commented that currently, there is no absolute cure to HCV, my mind immediately shifted to “cancer”. People often think of cancer as the most severe illness someone can get, because there is no cure. However, we forget that in actuality, there are numerous

Cindy Lattie Instructor: Virginia Sullivan HPR 232: Disease Process and Treatment November 8, 2014 Hepatitis C Case Study Outline I. Liver and Biliary System II. The liver is located beneath the diaphragm in the upper abdomen. The primary functions of the liver include: a. Production of bile b. Production of proteins for blood plasma c. Conversion of glucose into glycogen d. Regulation of amino acids in the blood e. Processing of hemoglobin f. Conversion of ammonia to urea g. Clearing drugs and toxic substances from the blood h. Regulating clotting of the blood i. Producing immune factors and removing bacteria from the bloodstream

Hepatitis C virus (HCV) infection causes chronic liver. Over time, infections can lead to liver damage, liver cancer, and even liver failure.

Medicaid officials across the country are pushing for the access to the new hepatitis C drugs to be widened by state Medicaid programs because the guidelines are unreasonably strict and these medications can cost up to $1,000 per pill. The Food and Drug Administration approved the new hepatitis C drugs, Sovaldi and Harvoni, on July 24 of this year. These expenses can cost up to $84,000 for the recommended treatment period of 12 weeks. The hepatitis C drugs can help cure thousands of people with hepatitis C, which is why Federal and State officials are pushing for access to these drugs to be widened.

Hepatitis C has been referred to as a "Silent Epidemic," since it usually progresses slowly over many years. Most people who are infected with hepatitis C are not aware of any noticeable symptoms for as long as one to two decades after they are infected. In fact, by the time symptoms appear, the virus has probably already begun to damage the liver. If the liver is injured and stops functioning, death will always be the outcome (Lieber). Liver failure from chronic hepatitis C is one of the most common causes of liver transplants in the United States.